ID   CDK8_HUMAN              Reviewed;         464 AA.
AC   P49336; Q5VUF3; Q6ISB5;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 1.
DT   12-OCT-2022, entry version 199.
DE   RecName: Full=Cyclin-dependent kinase 8;
DE            EC=2.7.11.22;
DE            EC=2.7.11.23;
DE   AltName: Full=Cell division protein kinase 8;
DE   AltName: Full=Mediator complex subunit CDK8;
DE   AltName: Full=Mediator of RNA polymerase II transcription subunit CDK8;
DE   AltName: Full=Protein kinase K35;
GN   Name=CDK8;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=7568034; DOI=10.1073/pnas.92.19.8871;
RA   Tassan J.-P., Jaquenoud M., Leopold P., Schultz S.J., Nigg E.A.;
RT   "Identification of human cyclin-dependent kinase 8, a putative protein
RT   kinase partner for cyclin C.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:8871-8875(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057823; DOI=10.1038/nature02379;
RA   Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L.,
RA   Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E., Griffiths-Jones S.,
RA   Jones M.C., Keenan S.J., Oliver K., Scott C.E., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Andrews D.T., Ashwell R.I.S., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Bannerjee R., Barlow K.F., Bates K., Beasley H., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M., Clegg S.C.,
RA   Cobley V., Collins J.E., Corby N., Coville G.J., Deloukas P., Dhami P.,
RA   Dunham I., Dunn M., Earthrowl M.E., Ellington A.G., Faulkner L.,
RA   Frankish A.G., Frankland J., French L., Garner P., Garnett J.,
RA   Gilbert J.G.R., Gilson C.J., Ghori J., Grafham D.V., Gribble S.M.,
RA   Griffiths C., Hall R.E., Hammond S., Harley J.L., Hart E.A., Heath P.D.,
RA   Howden P.J., Huckle E.J., Hunt P.J., Hunt A.R., Johnson C., Johnson D.,
RA   Kay M., Kimberley A.M., King A., Laird G.K., Langford C.J., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Lloyd C., Loveland J.E., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S.,
RA   Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I., Pelan S.,
RA   Phillimore B., Porter K.M., Rice C.M., Searle S., Sehra H.K., Shownkeen R.,
RA   Skuce C.D., Smith M., Steward C.A., Sycamore N., Tester J., Thomas D.W.,
RA   Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Wilming L., Wray P.W., Wright M.W., Young L.,
RA   Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Beck S., Bentley D.R.,
RA   Rogers J., Ross M.T.;
RT   "The DNA sequence and analysis of human chromosome 13.";
RL   Nature 428:522-528(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND IDENTIFICATION IN THE MEDIATOR
RP   COMPLEX.
RX   PubMed=9734358; DOI=10.1016/s1097-2765(00)80131-8;
RA   Sun X., Zhang Y., Cho H., Rickert P., Lees E., Lane W.S., Reinberg D.;
RT   "NAT, a human complex containing Srb polypeptides that functions as a
RT   negative regulator of activated transcription.";
RL   Mol. Cell 2:213-222(1998).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND IDENTIFICATION IN THE SMCC
RP   COMPLEX.
RX   PubMed=10024883; DOI=10.1016/s1097-2765(00)80178-1;
RA   Gu W., Malik S., Ito M., Yuan C.-X., Fondell J.D., Zhang X., Martinez E.,
RA   Qin J., Roeder R.G.;
RT   "A novel human SRB/MED-containing cofactor complex, SMCC, involved in
RT   transcription regulation.";
RL   Mol. Cell 3:97-108(1999).
RN   [7]
RP   ERRATUM OF PUBMED:10024883.
RA   Gu W., Malik S., Ito M., Yuan C.-X., Fondell J.D., Zhang X., Martinez E.,
RA   Qin J., Roeder R.G.;
RL   Mol. Cell 3:541-541(1999).
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF ASP-173.
RX   PubMed=10993082; DOI=10.1038/35024111;
RA   Akoulitchev S., Chuikov S., Reinberg D.;
RT   "TFIIH is negatively regulated by cdk8-containing mediator complexes.";
RL   Nature 407:102-106(2000).
RN   [9]
RP   FUNCTION, AND INTERACTION WITH MAML1.
RX   PubMed=15546612; DOI=10.1016/j.molcel.2004.10.014;
RA   Fryer C.J., White J.B., Jones K.A.;
RT   "Mastermind recruits CycC:CDK8 to phosphorylate the Notch ICD and
RT   coordinate activation with turnover.";
RL   Mol. Cell 16:509-520(2004).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND IDENTIFICATION IN THE MEDIATOR
RP   COMPLEX.
RX   PubMed=15175163; DOI=10.1016/j.molcel.2004.05.006;
RA   Sato S., Tomomori-Sato C., Parmely T.J., Florens L., Zybailov B.,
RA   Swanson S.K., Banks C.A.S., Jin J., Cai Y., Washburn M.P., Conaway J.W.,
RA   Conaway R.C.;
RT   "A set of consensus mammalian mediator subunits identified by
RT   multidimensional protein identification technology.";
RL   Mol. Cell 14:685-691(2004).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY, IDENTIFICATION IN THE MEDIATOR
RP   COMPLEX, AND ASSOCIATION OF THE MEDIATOR COMPLEX WITH RNA POLYMERASE II.
RX   PubMed=15989967; DOI=10.1016/j.molcel.2005.05.015;
RA   Zhang X., Krutchinsky A., Fukuda A., Chen W., Yamamura S., Chait B.T.,
RA   Roeder R.G.;
RT   "MED1/TRAP220 exists predominantly in a TRAP/Mediator subpopulation
RT   enriched in RNA polymerase II and is required for ER-mediated
RT   transcription.";
RL   Mol. Cell 19:89-100(2005).
RN   [12]
RP   INTERACTION WITH CTNNB1; GLI3; MED1; MED6; MED12 AND MED23.
RX   PubMed=17000779; DOI=10.1128/mcb.00443-06;
RA   Zhou H., Kim S., Ishii S., Boyer T.G.;
RT   "Mediator modulates Gli3-dependent Sonic hedgehog signaling.";
RL   Mol. Cell. Biol. 26:8667-8682(2006).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [14]
RP   INVOLVEMENT IN IDDHBA, VARIANTS IDDHBA LEU-27; GLY-29; SER-30; LEU-62;
RP   LEU-97; GLN-178; GLY-193 AND MET-223, CHARACTERIZATION OF VARIANTS IDDHBA
RP   LEU-27; GLY-29; SER-30; LEU-62; GLN-178; GLY-193 AND MET-223, FUNCTION, AND
RP   MUTAGENESIS OF ASP-173.
RX   PubMed=30905399; DOI=10.1016/j.ajhg.2019.02.006;
RG   Deciphering Developmental Disorders Study;
RA   Calpena E., Hervieu A., Kaserer T., Swagemakers S.M.A., Goos J.A.C.,
RA   Popoola O., Ortiz-Ruiz M.J., Barbaro-Dieber T., Bownass L., Brilstra E.H.,
RA   Brimble E., Foulds N., Grebe T.A., Harder A.V.E., Lees M.M., Monaghan K.G.,
RA   Newbury-Ecob R.A., Ong K.R., Osio D., Reynoso Santos F.J.,
RA   Ruzhnikov M.R.Z., Telegrafi A., van Binsbergen E., van Dooren M.F.,
RA   van der Spek P.J., Blagg J., Twigg S.R.F., Mathijssen I.M.J., Clarke P.A.,
RA   Wilkie A.O.M.;
RT   "De Novo Missense Substitutions in the Gene Encoding CDK8, a Regulator of
RT   the Mediator Complex, Cause a Syndromic Developmental Disorder.";
RL   Am. J. Hum. Genet. 104:709-720(2019).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 1-403 IN COMPLEX WITH CCNC AND
RP   INHIBITOR.
RX   PubMed=21806996; DOI=10.1016/j.jmb.2011.07.020;
RA   Schneider E.V., Bottcher J., Blaesse M., Neumann L., Huber R., Maskos K.;
RT   "The structure of CDK8/CycC implicates specificity in the CDK/cyclin family
RT   and reveals interaction with a deep pocket binder.";
RL   J. Mol. Biol. 412:251-266(2011).
RN   [16]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASN-189 AND CYS-424.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Component of the Mediator complex, a coactivator involved in
CC       regulated gene transcription of nearly all RNA polymerase II-dependent
CC       genes. Mediator functions as a bridge to convey information from gene-
CC       specific regulatory proteins to the basal RNA polymerase II
CC       transcription machinery. Mediator is recruited to promoters by direct
CC       interactions with regulatory proteins and serves as a scaffold for the
CC       assembly of a functional pre-initiation complex with RNA polymerase II
CC       and the general transcription factors. Phosphorylates the CTD (C-
CC       terminal domain) of the large subunit of RNA polymerase II (RNAp II),
CC       which may inhibit the formation of a transcription initiation complex.
CC       Phosphorylates CCNH leading to down-regulation of the TFIIH complex and
CC       transcriptional repression. Recruited through interaction with MAML1 to
CC       hyperphosphorylate the intracellular domain of NOTCH, leading to its
CC       degradation. {ECO:0000269|PubMed:10993082, ECO:0000269|PubMed:15546612,
CC       ECO:0000269|PubMed:30905399}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.22;
CC         Evidence={ECO:0000269|PubMed:10993082};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.22; Evidence={ECO:0000269|PubMed:10993082};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=[DNA-directed RNA polymerase] + ATP = ADP + H(+) + phospho-
CC         [DNA-directed RNA polymerase]; Xref=Rhea:RHEA:10216, Rhea:RHEA-
CC         COMP:11321, Rhea:RHEA-COMP:11322, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:43176, ChEBI:CHEBI:68546,
CC         ChEBI:CHEBI:456216; EC=2.7.11.23;
CC         Evidence={ECO:0000269|PubMed:10993082};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC   -!- SUBUNIT: Component of the Mediator complex, which is composed of MED1,
CC       MED4, MED6, MED7, MED8, MED9, MED10, MED11, MED12, MED13, MED13L,
CC       MED14, MED15, MED16, MED17, MED18, MED19, MED20, MED21, MED22, MED23,
CC       MED24, MED25, MED26, MED27, MED29, MED30, MED31, CCNC, CDK8 and
CC       CDC2L6/CDK11. The MED12, MED13, CCNC and CDK8 subunits form a distinct
CC       module termed the CDK8 module. Mediator containing the CDK8 module is
CC       less active than Mediator lacking this module in supporting
CC       transcriptional activation. Individual preparations of the Mediator
CC       complex lacking one or more distinct subunits have been variously
CC       termed ARC, CRSP, DRIP, PC2, SMCC and TRAP. The cylin/CDK pair formed
CC       by CCNC/CDK8 also associates with the large subunit of RNA polymerase
CC       II. Interacts with CTNNB1, GLI3 and MAML1.
CC       {ECO:0000269|PubMed:10024883, ECO:0000269|PubMed:15175163,
CC       ECO:0000269|PubMed:15546612, ECO:0000269|PubMed:15989967,
CC       ECO:0000269|PubMed:17000779, ECO:0000269|PubMed:21806996,
CC       ECO:0000269|PubMed:9734358}.
CC   -!- INTERACTION:
CC       P49336; P24863: CCNC; NbExp=37; IntAct=EBI-394377, EBI-395261;
CC       P49336; Q01094: E2F1; NbExp=3; IntAct=EBI-394377, EBI-448924;
CC       P49336-2; P02489: CRYAA; NbExp=3; IntAct=EBI-11039720, EBI-6875961;
CC       P49336-2; Q14204: DYNC1H1; NbExp=3; IntAct=EBI-11039720, EBI-356015;
CC       P49336-2; Q92876: KLK6; NbExp=3; IntAct=EBI-11039720, EBI-2432309;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P49336-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P49336-2; Sequence=VSP_029970;
CC   -!- DISEASE: Intellectual developmental disorder with hypotonia and
CC       behavioral abnormalities (IDDHBA) [MIM:618748]: An autosomal dominant
CC       neurodevelopmental disorder with onset in infancy. IDDHBA is
CC       characterized by hypotonia, global developmental delay, learning
CC       disability, and behavioral abnormalities, such as autistic features and
CC       attention deficit-hyperactivity disorder. Additional variable features
CC       may include non-specific facial dysmorphism, congenital heart defects,
CC       ocular anomalies, and poor feeding. {ECO:0000269|PubMed:30905399}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr
CC       protein kinase family. CDC2/CDKX subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X85753; CAA59754.1; -; mRNA.
DR   EMBL; AL159159; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL590108; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471075; EAX08386.1; -; Genomic_DNA.
DR   EMBL; CH471075; EAX08387.1; -; Genomic_DNA.
DR   EMBL; BC069634; AAH69634.1; -; mRNA.
DR   EMBL; BC104492; AAI04493.1; -; mRNA.
DR   EMBL; BC105950; AAI05951.1; -; mRNA.
DR   EMBL; BC107601; AAI07602.1; -; mRNA.
DR   CCDS; CCDS9317.1; -. [P49336-1]
DR   PIR; I37227; I37227.
DR   RefSeq; NP_001251.1; NM_001260.2. [P49336-1]
DR   RefSeq; NP_001305297.1; NM_001318368.1. [P49336-2]
DR   PDB; 3RGF; X-ray; 2.20 A; A=1-403.
DR   PDB; 4CRL; X-ray; 2.40 A; A=1-403.
DR   PDB; 4F6S; X-ray; 2.60 A; A=1-403.
DR   PDB; 4F6U; X-ray; 2.10 A; A=1-403.
DR   PDB; 4F6W; X-ray; 2.39 A; A=1-403.
DR   PDB; 4F70; X-ray; 3.00 A; A=1-403.
DR   PDB; 4F7J; X-ray; 2.60 A; A=1-403.
DR   PDB; 4F7L; X-ray; 2.90 A; A=1-403.
DR   PDB; 4F7N; X-ray; 2.65 A; A=1-403.
DR   PDB; 4F7S; X-ray; 2.20 A; A=1-403.
DR   PDB; 4G6L; X-ray; 2.70 A; A=1-403.
DR   PDB; 5BNJ; X-ray; 2.64 A; A=1-403.
DR   PDB; 5CEI; X-ray; 2.24 A; A=1-403.
DR   PDB; 5FGK; X-ray; 2.36 A; A=1-362.
DR   PDB; 5HBE; X-ray; 2.38 A; A=1-362.
DR   PDB; 5HBH; X-ray; 2.50 A; A=1-362.
DR   PDB; 5HBJ; X-ray; 3.00 A; A=1-362.
DR   PDB; 5HNB; X-ray; 2.35 A; A=1-362.
DR   PDB; 5HVY; X-ray; 2.39 A; A=1-403.
DR   PDB; 5I5Z; X-ray; 2.60 A; A=1-362.
DR   PDB; 5ICP; X-ray; 2.18 A; A=1-362.
DR   PDB; 5IDN; X-ray; 2.26 A; A=1-364.
DR   PDB; 5IDP; X-ray; 2.65 A; A=1-364.
DR   PDB; 5XQX; X-ray; 2.30 A; A=1-371.
DR   PDB; 5XS2; X-ray; 2.04 A; A=1-371.
DR   PDB; 6QTG; X-ray; 2.70 A; A=1-403.
DR   PDB; 6QTJ; X-ray; 2.48 A; A=1-403.
DR   PDB; 6R3S; X-ray; 2.19 A; A=1-403.
DR   PDB; 6T41; X-ray; 2.45 A; A=1-404.
DR   PDB; 6TPA; X-ray; 2.80 A; A=1-403.
DR   PDB; 6Y0A; X-ray; 2.19 A; A=1-403.
DR   PDBsum; 3RGF; -.
DR   PDBsum; 4CRL; -.
DR   PDBsum; 4F6S; -.
DR   PDBsum; 4F6U; -.
DR   PDBsum; 4F6W; -.
DR   PDBsum; 4F70; -.
DR   PDBsum; 4F7J; -.
DR   PDBsum; 4F7L; -.
DR   PDBsum; 4F7N; -.
DR   PDBsum; 4F7S; -.
DR   PDBsum; 4G6L; -.
DR   PDBsum; 5BNJ; -.
DR   PDBsum; 5CEI; -.
DR   PDBsum; 5FGK; -.
DR   PDBsum; 5HBE; -.
DR   PDBsum; 5HBH; -.
DR   PDBsum; 5HBJ; -.
DR   PDBsum; 5HNB; -.
DR   PDBsum; 5HVY; -.
DR   PDBsum; 5I5Z; -.
DR   PDBsum; 5ICP; -.
DR   PDBsum; 5IDN; -.
DR   PDBsum; 5IDP; -.
DR   PDBsum; 5XQX; -.
DR   PDBsum; 5XS2; -.
DR   PDBsum; 6QTG; -.
DR   PDBsum; 6QTJ; -.
DR   PDBsum; 6R3S; -.
DR   PDBsum; 6T41; -.
DR   PDBsum; 6TPA; -.
DR   PDBsum; 6Y0A; -.
DR   AlphaFoldDB; P49336; -.
DR   SMR; P49336; -.
DR   BioGRID; 107458; 215.
DR   ComplexPortal; CPX-1969; Cyclin C-CDK8 complex.
DR   ComplexPortal; CPX-3232; CKM complex variant 1.
DR   CORUM; P49336; -.
DR   DIP; DIP-32595N; -.
DR   IntAct; P49336; 197.
DR   MINT; P49336; -.
DR   STRING; 9606.ENSP00000370938; -.
DR   BindingDB; P49336; -.
DR   ChEMBL; CHEMBL5719; -.
DR   DrugBank; DB03496; Alvocidib.
DR   DrugCentral; P49336; -.
DR   GuidetoPHARMACOLOGY; 1980; -.
DR   GlyGen; P49336; 3 sites, 1 O-linked glycan (3 sites).
DR   iPTMnet; P49336; -.
DR   PhosphoSitePlus; P49336; -.
DR   BioMuta; CDK8; -.
DR   DMDM; 1345718; -.
DR   EPD; P49336; -.
DR   jPOST; P49336; -.
DR   MassIVE; P49336; -.
DR   MaxQB; P49336; -.
DR   PaxDb; P49336; -.
DR   PeptideAtlas; P49336; -.
DR   PRIDE; P49336; -.
DR   ProteomicsDB; 55991; -. [P49336-1]
DR   ProteomicsDB; 55992; -. [P49336-2]
DR   Antibodypedia; 7248; 462 antibodies from 36 providers.
DR   DNASU; 1024; -.
DR   Ensembl; ENST00000381527.8; ENSP00000370938.3; ENSG00000132964.12. [P49336-1]
DR   GeneID; 1024; -.
DR   KEGG; hsa:1024; -.
DR   MANE-Select; ENST00000381527.8; ENSP00000370938.3; NM_001260.3; NP_001251.1.
DR   UCSC; uc001uqr.2; human. [P49336-1]
DR   CTD; 1024; -.
DR   DisGeNET; 1024; -.
DR   GeneCards; CDK8; -.
DR   HGNC; HGNC:1779; CDK8.
DR   HPA; ENSG00000132964; Low tissue specificity.
DR   MalaCards; CDK8; -.
DR   MIM; 603184; gene.
DR   MIM; 618748; phenotype.
DR   neXtProt; NX_P49336; -.
DR   OpenTargets; ENSG00000132964; -.
DR   PharmGKB; PA26315; -.
DR   VEuPathDB; HostDB:ENSG00000132964; -.
DR   eggNOG; KOG0666; Eukaryota.
DR   GeneTree; ENSGT00940000157104; -.
DR   HOGENOM; CLU_000288_181_6_1; -.
DR   InParanoid; P49336; -.
DR   OMA; VYLHRNW; -.
DR   OrthoDB; 642369at2759; -.
DR   PhylomeDB; P49336; -.
DR   TreeFam; TF101025; -.
DR   BRENDA; 2.7.11.22; 2681.
DR   BRENDA; 2.7.11.23; 2681.
DR   PathwayCommons; P49336; -.
DR   Reactome; R-HSA-1989781; PPARA activates gene expression.
DR   Reactome; R-HSA-2122947; NOTCH1 Intracellular Domain Regulates Transcription.
DR   Reactome; R-HSA-212436; Generic Transcription Pathway.
DR   Reactome; R-HSA-2173796; SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription.
DR   Reactome; R-HSA-2644606; Constitutive Signaling by NOTCH1 PEST Domain Mutants.
DR   Reactome; R-HSA-2894862; Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants.
DR   Reactome; R-HSA-381340; Transcriptional regulation of white adipocyte differentiation.
DR   SignaLink; P49336; -.
DR   SIGNOR; P49336; -.
DR   BioGRID-ORCS; 1024; 41 hits in 1043 CRISPR screens.
DR   ChiTaRS; CDK8; human.
DR   GeneWiki; Cyclin-dependent_kinase_8; -.
DR   GenomeRNAi; 1024; -.
DR   Pharos; P49336; Tchem.
DR   PRO; PR:P49336; -.
DR   Proteomes; UP000005640; Chromosome 13.
DR   RNAct; P49336; protein.
DR   Bgee; ENSG00000132964; Expressed in adrenal tissue and 206 other tissues.
DR   ExpressionAtlas; P49336; baseline and differential.
DR   Genevisible; P49336; HS.
DR   GO; GO:0016592; C:mediator complex; IDA:MGI.
DR   GO; GO:0005730; C:nucleolus; IDA:MGI.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:MGI.
DR   GO; GO:0032991; C:protein-containing complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004693; F:cyclin-dependent protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0004672; F:protein kinase activity; IMP:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0008353; F:RNA polymerase II CTD heptapeptide repeat kinase activity; IBA:GO_Central.
DR   GO; GO:0006468; P:protein phosphorylation; IBA:GO_Central.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing; ATP-binding;
KW   Autism spectrum disorder; Disease variant; Intellectual disability; Kinase;
KW   Nucleotide-binding; Nucleus; Reference proteome; Repressor;
KW   Serine/threonine-protein kinase; Transcription; Transcription regulation;
KW   Transferase.
FT   CHAIN           1..464
FT                   /note="Cyclin-dependent kinase 8"
FT                   /id="PRO_0000085797"
FT   DOMAIN          21..335
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..15
FT                   /note="Interaction with CCNC"
FT   REGION          361..464
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        373..398
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        412..464
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        151
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         27..35
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         52
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   VAR_SEQ         370
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_029970"
FT   VARIANT         27
FT                   /note="V -> L (in IDDHBA; decreased protein kinase
FT                   activity)"
FT                   /evidence="ECO:0000269|PubMed:30905399"
FT                   /id="VAR_083786"
FT   VARIANT         29
FT                   /note="R -> G (in IDDHBA; decreased protein kinase
FT                   activity; dbSNP:rs1593218885)"
FT                   /evidence="ECO:0000269|PubMed:30905399"
FT                   /id="VAR_083787"
FT   VARIANT         30
FT                   /note="G -> S (in IDDHBA; decreased protein kinase
FT                   activity; dbSNP:rs1593218890)"
FT                   /evidence="ECO:0000269|PubMed:30905399"
FT                   /id="VAR_083788"
FT   VARIANT         62
FT                   /note="S -> L (in IDDHBA; decreased protein kinase
FT                   activity; dbSNP:rs1565977796)"
FT                   /evidence="ECO:0000269|PubMed:30905399"
FT                   /id="VAR_083789"
FT   VARIANT         97
FT                   /note="F -> L (in IDDHBA; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:30905399"
FT                   /id="VAR_083790"
FT   VARIANT         178
FT                   /note="R -> Q (in IDDHBA; decreased protein kinase
FT                   activity; dbSNP:rs1418353379)"
FT                   /evidence="ECO:0000269|PubMed:30905399"
FT                   /id="VAR_083791"
FT   VARIANT         189
FT                   /note="D -> N (in a lung neuroendocrine carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041980"
FT   VARIANT         193
FT                   /note="V -> G (in IDDHBA; decreased protein kinase
FT                   activity)"
FT                   /evidence="ECO:0000269|PubMed:30905399"
FT                   /id="VAR_083792"
FT   VARIANT         223
FT                   /note="I -> M (in IDDHBA; decreased protein kinase
FT                   activity; dbSNP:rs1593310364)"
FT                   /evidence="ECO:0000269|PubMed:30905399"
FT                   /id="VAR_083793"
FT   VARIANT         424
FT                   /note="R -> C (in a colorectal adenocarcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041981"
FT   MUTAGEN         173
FT                   /note="D->A: Abrogates kinase activity and TFIIH-dependent
FT                   transcriptional repression."
FT                   /evidence="ECO:0000269|PubMed:10993082,
FT                   ECO:0000269|PubMed:30905399"
FT   HELIX           3..12
FT                   /evidence="ECO:0007829|PDB:5XS2"
FT   HELIX           16..19
FT                   /evidence="ECO:0007829|PDB:5XS2"
FT   STRAND          26..30
FT                   /evidence="ECO:0007829|PDB:5XS2"
FT   STRAND          33..44
FT                   /evidence="ECO:0007829|PDB:5XS2"
FT   STRAND          49..58
FT                   /evidence="ECO:0007829|PDB:5XS2"
FT   HELIX           61..72
FT                   /evidence="ECO:0007829|PDB:5XS2"
FT   STRAND          83..87
FT                   /evidence="ECO:0007829|PDB:5XS2"
FT   TURN            88..91
FT                   /evidence="ECO:0007829|PDB:5XS2"
FT   STRAND          92..98
FT                   /evidence="ECO:0007829|PDB:5XS2"
FT   STRAND          101..103
FT                   /evidence="ECO:0007829|PDB:5XS2"
FT   HELIX           104..115
FT                   /evidence="ECO:0007829|PDB:5XS2"
FT   TURN            116..118
FT                   /evidence="ECO:0007829|PDB:5XS2"
FT   HELIX           125..144
FT                   /evidence="ECO:0007829|PDB:5XS2"
FT   HELIX           154..156
FT                   /evidence="ECO:0007829|PDB:5XS2"
FT   STRAND          157..159
FT                   /evidence="ECO:0007829|PDB:5XS2"
FT   TURN            164..167
FT                   /evidence="ECO:0007829|PDB:5XS2"
FT   STRAND          169..171
FT                   /evidence="ECO:0007829|PDB:5XS2"
FT   TURN            174..178
FT                   /evidence="ECO:0007829|PDB:6TPA"
FT   HELIX           179..181
FT                   /evidence="ECO:0007829|PDB:5ICP"
FT   STRAND          186..188
FT                   /evidence="ECO:0007829|PDB:5XS2"
FT   HELIX           202..205
FT                   /evidence="ECO:0007829|PDB:5XS2"
FT   HELIX           213..229
FT                   /evidence="ECO:0007829|PDB:5XS2"
FT   HELIX           249..259
FT                   /evidence="ECO:0007829|PDB:5XS2"
FT   TURN            264..266
FT                   /evidence="ECO:0007829|PDB:5XS2"
FT   HELIX           268..272
FT                   /evidence="ECO:0007829|PDB:5XS2"
FT   HELIX           276..282
FT                   /evidence="ECO:0007829|PDB:5XS2"
FT   HELIX           285..288
FT                   /evidence="ECO:0007829|PDB:5XS2"
FT   HELIX           293..299
FT                   /evidence="ECO:0007829|PDB:5XS2"
FT   HELIX           307..315
FT                   /evidence="ECO:0007829|PDB:5XS2"
FT   HELIX           320..322
FT                   /evidence="ECO:0007829|PDB:5XS2"
FT   HELIX           326..330
FT                   /evidence="ECO:0007829|PDB:5XS2"
FT   HELIX           333..335
FT                   /evidence="ECO:0007829|PDB:5XS2"
FT   STRAND          337..339
FT                   /evidence="ECO:0007829|PDB:5XS2"
FT   TURN            345..348
FT                   /evidence="ECO:0007829|PDB:5XS2"
SQ   SEQUENCE   464 AA;  53284 MW;  00CBAB6CE354605F CRC64;
     MDYDFKVKLS SERERVEDLF EYEGCKVGRG TYGHVYKAKR KDGKDDKDYA LKQIEGTGIS
     MSACREIALL RELKHPNVIS LQKVFLSHAD RKVWLLFDYA EHDLWHIIKF HRASKANKKP
     VQLPRGMVKS LLYQILDGIH YLHANWVLHR DLKPANILVM GEGPERGRVK IADMGFARLF
     NSPLKPLADL DPVVVTFWYR APELLLGARH YTKAIDIWAI GCIFAELLTS EPIFHCRQED
     IKTSNPYHHD QLDRIFNVMG FPADKDWEDI KKMPEHSTLM KDFRRNTYTN CSLIKYMEKH
     KVKPDSKAFH LLQKLLTMDP IKRITSEQAM QDPYFLEDPL PTSDVFAGCQ IPYPKREFLT
     EEEPDDKGDK KNQQQQQGNN HTNGTGHPGN QDSSHTQGPP LKKVRVVPPT TTSGGLIMTS
     DYQRSNPHAA YPNPGPSTSQ PQSSMGYSAT SQQPPQYSHQ THRY
//
